The global market for PD-1 Antibody Drug was valued at US$ 42573 million in the year 2024 and is projected to reach a revised size of US$ 87073 million by 2031, growing at a CAGR of 11.2% during the forecast period.

PD-1 Antibody Drug Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on PD-1 Antibody Drug competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

A PD-1 antibody drug is a monoclonal antibody that targets the Programmed Death-1 receptor to block the PD-1/PD-L1 immune-checkpoint pathway exploited by tumor cells, thereby restoring and enhancing T-cell antitumor activity. These products are typically manufactured using mammalian expression systems such as CHO cells in large-scale bioreactors, followed by protein purification, viral inactivation/clearance, formulation, and aseptic fill-finish. The upstream supply chain includes key raw materials such as cell-culture media, recombinant expression vectors, single-use bioreactor bags, chromatography resins, filtration membranes, buffers, stabilizers, and excipients, as well as critical bioprocess equipment including bioreactors, chromatography and filtration systems, in-line monitoring sensors, and aseptic filling lines. The overall value chain involves stringent quality control and GMP compliance and forms a high-barrier manufacturing ecosystem supporting modern cancer immunotherapy.In 2024, global sales of PD-1 antibody drugs reached 22.88 million vials, with an average price of USD 1,860 per vial, and corporate gross profit margins ranging between 60% and 70%.

In recent years, PD-1 antibody therapies have been incorporated into standard treatment pathways across multiple tumor types, with both real-world evidence and clinical trials demonstrating durable responses and manageable immune-related adverse events. This has established PD-1 inhibitors as a central component of modern cancer immunotherapy. At the same time, the competitive landscape has expanded from a few originator companies to a diverse environment including biosimilars, localized biologics, and next-generation formulations such as subcutaneous, long-acting, and bispecific candidates, reshaping prescribing trends and patient access patterns.

Looking ahead, several development directions are expected to shape the market. Combination therapies and indication expansion will continue to push therapeutic boundaries, including integration with targeted therapies, antibody-drug conjugates, and cell-based treatments. Patient stratification guided by biomarkers will make treatment more precise. Innovations in delivery route and formulation—such as subcutaneous injections, long-acting constructs, and biosimilars—will improve accessibility and influence pricing structures. Meanwhile, the emergence of bispecific and multi-target immunotherapies is becoming a crucial competitive direction for the next generation of oncology treatments.

Multiple forces are driving market expansion, including accumulating efficacy evidence that broadens clinical use, updates to medical guidelines, and increased adoption by oncologists. Regulatory bodies in several regions are speeding up reviews when sufficient evidence is available, and reimbursement mechanisms are gradually extending to immunotherapies. Advances in bioprocessing, single-use technologies, and contract manufacturing are strengthening manufacturing reliability and supporting regionalized production. At the same time, substantial differences in access and reimbursement across regions compel companies to adjust commercialization and localization strategies.

Despite this momentum, the field faces notable challenges. Immune-related adverse events require sustained management and education. In some tumor types, limited clinical benefit restricts the applicability of high-cost combination regimens. Increasing competition from biosimilars, domestic manufacturers, and novel modalities is driving price pressure and eroding market share for established therapies. Regulatory complexity, intellectual-property disputes, reimbursement negotiations, and uncertainty in the supply chain—exacerbated by geopolitical dynamics—all introduce risks that may affect commercialization timelines and global expansion strategies for PD-1 antibody drugs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for PD-1 Antibody Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PD-1 Antibody Drug.

The PD-1 Antibody Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global PD-1 Antibody Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, by Dosage Strength and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the PD-1 Antibody Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, by Dosage Strength and by regions.

Scope of PD-1 Antibody Drug Market Report

Report Metric	Details
Report Name	PD-1 Antibody Drug Market
Accounted market size in year	US$ 42573 million
Forecasted market size in 2031	US$ 87073 million
CAGR	11.2%
Base Year	year
Forecasted years	2026 - 2031
Segment by Type	Pembrolizumab Nivolumab Cemiplimab Toripalimab Sintilimab Tislelizumab Camrelizumab Penpulimab Retifanlimab Zimberelimab
Segment by Dosage Strength	100 mg / Vial 200 mg / Vial 240 mg / Vial Others
Segment by Injection Method	Intravenous Injection Subcutaneous Injection
Segment by Application	Hospital Clinic Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Merck & Co., Inc., Bristol-Myers Squibb, Regeneron Pharmaceuticals, Shanghai Junshi Biosciences, Innovent Biologics, Hengrui Pharma, BeiGene, Akeso, Inc., Zai Lab, GSK, Eisai
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of PD-1 Antibody Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of PD-1 Antibody Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is PD-1 Antibody Drug Market growing?

Ans: The PD-1 Antibody Drug Market witnessing a CAGR of 11.2% during the forecast period 2026-2031.

What is the PD-1 Antibody Drug Market size in 2031?

Ans: The PD-1 Antibody Drug Market size in 2031 will be US$ 87073 million.

Who are the main players in the PD-1 Antibody Drug Market report?

Ans: The main players in the PD-1 Antibody Drug Market are Merck & Co., Inc., Bristol-Myers Squibb, Regeneron Pharmaceuticals, Shanghai Junshi Biosciences, Innovent Biologics, Hengrui Pharma, BeiGene, Akeso, Inc., Zai Lab, GSK, Eisai

What are the Application segmentation covered in the PD-1 Antibody Drug Market report?

Ans: The Applications covered in the PD-1 Antibody Drug Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the PD-1 Antibody Drug Market report?

Ans: The Types covered in the PD-1 Antibody Drug Market report are Pembrolizumab, Nivolumab, Cemiplimab, Toripalimab, Sintilimab, Tislelizumab, Camrelizumab, Penpulimab, Retifanlimab, Zimberelimab

1 PD-1 Antibody Drug Market Overview

1.1 Product Definition

1.2 PD-1 Antibody Drug by Type

1.2.1 Global PD-1 Antibody Drug Market Value Comparison by Type (2024 VS 2031)

1.2.2 Pembrolizumab

1.2.3 Nivolumab

1.2.4 Cemiplimab

1.2.5 Toripalimab

1.2.6 Sintilimab

1.2.7 Tislelizumab

1.2.8 Camrelizumab

1.2.9 Penpulimab

1.2.10 Retifanlimab

1.3 PD-1 Antibody Drug by Dosage Strength

1.3.1 Global PD-1 Antibody Drug Market Value Comparison by Dosage Strength: 2024 VS 2031

1.3.2 100 mg / Vial

1.3.3 200 mg / Vial

1.3.4 240 mg / Vial

1.3.5 Others

1.4 PD-1 Antibody Drug by Injection Method

1.4.1 Global PD-1 Antibody Drug Market Value Comparison by Injection Method: 2024 VS 2031

1.4.2 Intravenous Injection

1.4.3 Subcutaneous Injection

1.5 PD-1 Antibody Drug by Application

1.5.1 Global PD-1 Antibody Drug Market Value by Application (2024 VS 2031)

1.5.2 Hospital

1.5.3 Clinic

1.5.4 Other

1.6 Global PD-1 Antibody Drug Market Size Estimates and Forecasts

1.6.1 Global PD-1 Antibody Drug Revenue 2020-2031

1.6.2 Global PD-1 Antibody Drug Sales 2020-2031

1.6.3 Global PD-1 Antibody Drug Market Average Price (2020-2031)

1.7 Assumptions and Limitations

2 PD-1 Antibody Drug Market Competition by Manufacturers

2.1 Global PD-1 Antibody Drug Sales Market Share by Manufacturers (2020-2025)

2.2 Global PD-1 Antibody Drug Revenue Market Share by Manufacturers (2020-2025)

2.3 Global PD-1 Antibody Drug Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of PD-1 Antibody Drug, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of PD-1 Antibody Drug, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of PD-1 Antibody Drug, Product Type & Application

2.7 Global Key Manufacturers of PD-1 Antibody Drug, Date of Enter into This Industry

2.8 Global PD-1 Antibody Drug Market Competitive Situation and Trends

2.8.1 Global PD-1 Antibody Drug Market Concentration Rate

2.8.2 The Global 5 and 10 Largest PD-1 Antibody Drug Players Market Share by Revenue

2.8.3 Global PD-1 Antibody Drug Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global PD-1 Antibody Drug Market Scenario by Region

3.1 Global PD-1 Antibody Drug Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global PD-1 Antibody Drug Sales by Region: 2020-2031

3.2.1 Global PD-1 Antibody Drug Sales by Region: 2020-2025

3.2.2 Global PD-1 Antibody Drug Sales by Region: 2026-2031

3.3 Global PD-1 Antibody Drug Revenue by Region: 2020-2031

3.3.1 Global PD-1 Antibody Drug Revenue by Region: 2020-2025

3.3.2 Global PD-1 Antibody Drug Revenue by Region: 2026-2031

3.4 North America PD-1 Antibody Drug Market Facts & Figures by Country

3.4.1 North America PD-1 Antibody Drug Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America PD-1 Antibody Drug Sales by Country (2020-2031)

3.4.3 North America PD-1 Antibody Drug Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe PD-1 Antibody Drug Market Facts & Figures by Country

3.5.1 Europe PD-1 Antibody Drug Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe PD-1 Antibody Drug Sales by Country (2020-2031)

3.5.3 Europe PD-1 Antibody Drug Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific PD-1 Antibody Drug Market Facts & Figures by Region

3.6.1 Asia Pacific PD-1 Antibody Drug Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific PD-1 Antibody Drug Sales by Region (2020-2031)

3.6.3 Asia Pacific PD-1 Antibody Drug Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America PD-1 Antibody Drug Market Facts & Figures by Country

3.7.1 Latin America PD-1 Antibody Drug Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America PD-1 Antibody Drug Sales by Country (2020-2031)

3.7.3 Latin America PD-1 Antibody Drug Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa PD-1 Antibody Drug Market Facts & Figures by Country

3.8.1 Middle East and Africa PD-1 Antibody Drug Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa PD-1 Antibody Drug Sales by Country (2020-2031)

3.8.3 Middle East and Africa PD-1 Antibody Drug Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global PD-1 Antibody Drug Sales by Type (2020-2031)

4.1.1 Global PD-1 Antibody Drug Sales by Type (2020-2025)

4.1.2 Global PD-1 Antibody Drug Sales by Type (2026-2031)

4.1.3 Global PD-1 Antibody Drug Sales Market Share by Type (2020-2031)

4.2 Global PD-1 Antibody Drug Revenue by Type (2020-2031)

4.2.1 Global PD-1 Antibody Drug Revenue by Type (2020-2025)

4.2.2 Global PD-1 Antibody Drug Revenue by Type (2026-2031)

4.2.3 Global PD-1 Antibody Drug Revenue Market Share by Type (2020-2031)

4.3 Global PD-1 Antibody Drug Price by Type (2020-2031)

5 Segment by Application

5.1 Global PD-1 Antibody Drug Sales by Application (2020-2031)

5.1.1 Global PD-1 Antibody Drug Sales by Application (2020-2025)

5.1.2 Global PD-1 Antibody Drug Sales by Application (2026-2031)

5.1.3 Global PD-1 Antibody Drug Sales Market Share by Application (2020-2031)

5.2 Global PD-1 Antibody Drug Revenue by Application (2020-2031)

5.2.1 Global PD-1 Antibody Drug Revenue by Application (2020-2025)

5.2.2 Global PD-1 Antibody Drug Revenue by Application (2026-2031)

5.2.3 Global PD-1 Antibody Drug Revenue Market Share by Application (2020-2031)

5.3 Global PD-1 Antibody Drug Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Merck & Co., Inc.

6.1.1 Merck & Co., Inc. Company Information

6.1.2 Merck & Co., Inc. Description and Business Overview

6.1.3 Merck & Co., Inc. PD-1 Antibody Drug Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Merck & Co., Inc. PD-1 Antibody Drug Product Portfolio

6.1.5 Merck & Co., Inc. Recent Developments/Updates

6.2 Bristol-Myers Squibb

6.2.1 Bristol-Myers Squibb Company Information

6.2.2 Bristol-Myers Squibb Description and Business Overview

6.2.3 Bristol-Myers Squibb PD-1 Antibody Drug Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Bristol-Myers Squibb PD-1 Antibody Drug Product Portfolio

6.2.5 Bristol-Myers Squibb Recent Developments/Updates

6.3 Regeneron Pharmaceuticals

6.3.1 Regeneron Pharmaceuticals Company Information

6.3.2 Regeneron Pharmaceuticals Description and Business Overview

6.3.3 Regeneron Pharmaceuticals PD-1 Antibody Drug Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Regeneron Pharmaceuticals PD-1 Antibody Drug Product Portfolio

6.3.5 Regeneron Pharmaceuticals Recent Developments/Updates

6.4 Shanghai Junshi Biosciences

6.4.1 Shanghai Junshi Biosciences Company Information

6.4.2 Shanghai Junshi Biosciences Description and Business Overview

6.4.3 Shanghai Junshi Biosciences PD-1 Antibody Drug Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Shanghai Junshi Biosciences PD-1 Antibody Drug Product Portfolio

6.4.5 Shanghai Junshi Biosciences Recent Developments/Updates

6.5 Innovent Biologics

6.5.1 Innovent Biologics Company Information

6.5.2 Innovent Biologics Description and Business Overview

6.5.3 Innovent Biologics PD-1 Antibody Drug Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Innovent Biologics PD-1 Antibody Drug Product Portfolio

6.5.5 Innovent Biologics Recent Developments/Updates

6.6 Hengrui Pharma

6.6.1 Hengrui Pharma Company Information

6.6.2 Hengrui Pharma Description and Business Overview

6.6.3 Hengrui Pharma PD-1 Antibody Drug Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Hengrui Pharma PD-1 Antibody Drug Product Portfolio

6.6.5 Hengrui Pharma Recent Developments/Updates

6.7 BeiGene

6.7.1 BeiGene Company Information

6.7.2 BeiGene Description and Business Overview

6.7.3 BeiGene PD-1 Antibody Drug Sales, Revenue and Gross Margin (2020-2025)

6.7.4 BeiGene PD-1 Antibody Drug Product Portfolio

6.7.5 BeiGene Recent Developments/Updates

6.8 Akeso, Inc.

6.8.1 Akeso, Inc. Company Information

6.8.2 Akeso, Inc. Description and Business Overview

6.8.3 Akeso, Inc. PD-1 Antibody Drug Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Akeso, Inc. PD-1 Antibody Drug Product Portfolio

6.8.5 Akeso, Inc. Recent Developments/Updates

6.9 Zai Lab

6.9.1 Zai Lab Company Information

6.9.2 Zai Lab Description and Business Overview

6.9.3 Zai Lab PD-1 Antibody Drug Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Zai Lab PD-1 Antibody Drug Product Portfolio

6.9.5 Zai Lab Recent Developments/Updates

6.10 GSK

6.10.1 GSK Company Information

6.10.2 GSK Description and Business Overview

6.10.3 GSK PD-1 Antibody Drug Sales, Revenue and Gross Margin (2020-2025)

6.10.4 GSK PD-1 Antibody Drug Product Portfolio

6.10.5 GSK Recent Developments/Updates

6.11 Eisai

6.11.1 Eisai Company Information

6.11.2 Eisai Description and Business Overview

6.11.3 Eisai PD-1 Antibody Drug Sales, Revenue and Gross Margin (2020-2025)

6.11.4 Eisai PD-1 Antibody Drug Product Portfolio

6.11.5 Eisai Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 PD-1 Antibody Drug Industry Chain Analysis

7.2 PD-1 Antibody Drug Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 PD-1 Antibody Drug Production Mode & Process Analysis

7.4 PD-1 Antibody Drug Sales and Marketing

7.4.1 PD-1 Antibody Drug Sales Channels

7.4.2 PD-1 Antibody Drug Distributors

7.5 PD-1 Antibody Drug Customer Analysis

8 PD-1 Antibody Drug Market Dynamics

8.1 PD-1 Antibody Drug Industry Trends

8.2 PD-1 Antibody Drug Market Drivers

8.3 PD-1 Antibody Drug Market Challenges

8.4 PD-1 Antibody Drug Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Bristol–Myers Squibb

BeiGene Ltd

Merck& Co. Inc

Regeneron Pharmaceuticals

Shanghai Junshi Biosciences

List of Tables

Table 1. Global PD-1 Antibody Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global PD-1 Antibody Drug Market Value by Dosage Strength, (US$ Million) & (2024 VS 2031)

Table 3. Global PD-1 Antibody Drug Market Value by Injection Method, (US$ Million) & (2024 VS 2031)

Table 4. Global PD-1 Antibody Drug Market Value by Application (2024 VS 2031) & (US$ Million)

Table 5. Global PD-1 Antibody Drug Market Competitive Situation by Manufacturers in 2024

Table 6. Global PD-1 Antibody Drug Sales (K Units) of Key Manufacturers (2020-2025)

Table 7. Global PD-1 Antibody Drug Sales Market Share by Manufacturers (2020-2025)

Table 8. Global PD-1 Antibody Drug Revenue (US$ Million) by Manufacturers (2020-2025)

Table 9. Global PD-1 Antibody Drug Revenue Share by Manufacturers (2020-2025)

Table 10. Global Market PD-1 Antibody Drug Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 11. Global Key Players of PD-1 Antibody Drug, Industry Ranking, 2022 VS 2023 VS 2024

Table 12. Global Key Manufacturers of PD-1 Antibody Drug, Manufacturing Sites & Headquarters

Table 13. Global Key Manufacturers of PD-1 Antibody Drug, Product Type & Application

Table 14. Global Key Manufacturers of PD-1 Antibody Drug, Date of Enter into This Industry

Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 16. Global PD-1 Antibody Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-1 Antibody Drug as of 2024)

Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 18. Global PD-1 Antibody Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 19. Global PD-1 Antibody Drug Sales by Region (2020-2025) & (K Units)

Table 20. Global PD-1 Antibody Drug Sales Market Share by Region (2020-2025)

Table 21. Global PD-1 Antibody Drug Sales by Region (2026-2031) & (K Units)

Table 22. Global PD-1 Antibody Drug Sales Market Share by Region (2026-2031)

Table 23. Global PD-1 Antibody Drug Revenue by Region (2020-2025) & (US$ Million)

Table 24. Global PD-1 Antibody Drug Revenue Market Share by Region (2020-2025)

Table 25. Global PD-1 Antibody Drug Revenue by Region (2026-2031) & (US$ Million)

Table 26. Global PD-1 Antibody Drug Revenue Market Share by Region (2026-2031)

Table 27. North America PD-1 Antibody Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 28. North America PD-1 Antibody Drug Sales by Country (2020-2025) & (K Units)

Table 29. North America PD-1 Antibody Drug Sales by Country (2026-2031) & (K Units)

Table 30. North America PD-1 Antibody Drug Revenue by Country (2020-2025) & (US$ Million)

Table 31. North America PD-1 Antibody Drug Revenue by Country (2026-2031) & (US$ Million)

Table 32. Europe PD-1 Antibody Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 33. Europe PD-1 Antibody Drug Sales by Country (2020-2025) & (K Units)

Table 34. Europe PD-1 Antibody Drug Sales by Country (2026-2031) & (K Units)

Table 35. Europe PD-1 Antibody Drug Revenue by Country (2020-2025) & (US$ Million)

Table 36. Europe PD-1 Antibody Drug Revenue by Country (2026-2031) & (US$ Million)

Table 37. Asia Pacific PD-1 Antibody Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 38. Asia Pacific PD-1 Antibody Drug Sales by Region (2020-2025) & (K Units)

Table 39. Asia Pacific PD-1 Antibody Drug Sales by Region (2026-2031) & (K Units)

Table 40. Asia Pacific PD-1 Antibody Drug Revenue by Region (2020-2025) & (US$ Million)

Table 41. Asia Pacific PD-1 Antibody Drug Revenue by Region (2026-2031) & (US$ Million)

Table 42. Latin America PD-1 Antibody Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 43. Latin America PD-1 Antibody Drug Sales by Country (2020-2025) & (K Units)

Table 44. Latin America PD-1 Antibody Drug Sales by Country (2026-2031) & (K Units)

Table 45. Latin America PD-1 Antibody Drug Revenue by Country (2020-2025) & (US$ Million)

Table 46. Latin America PD-1 Antibody Drug Revenue by Country (2026-2031) & (US$ Million)

Table 47. Middle East and Africa PD-1 Antibody Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 48. Middle East and Africa PD-1 Antibody Drug Sales by Country (2020-2025) & (K Units)

Table 49. Middle East and Africa PD-1 Antibody Drug Sales by Country (2026-2031) & (K Units)

Table 50. Middle East and Africa PD-1 Antibody Drug Revenue by Country (2020-2025) & (US$ Million)

Table 51. Middle East and Africa PD-1 Antibody Drug Revenue by Country (2026-2031) & (US$ Million)

Table 52. Global PD-1 Antibody Drug Sales (K Units) by Type (2020-2025)

Table 53. Global PD-1 Antibody Drug Sales (K Units) by Type (2026-2031)

Table 54. Global PD-1 Antibody Drug Sales Market Share by Type (2020-2025)

Table 55. Global PD-1 Antibody Drug Sales Market Share by Type (2026-2031)

Table 56. Global PD-1 Antibody Drug Revenue (US$ Million) by Type (2020-2025)

Table 57. Global PD-1 Antibody Drug Revenue (US$ Million) by Type (2026-2031)

Table 58. Global PD-1 Antibody Drug Revenue Market Share by Type (2020-2025)

Table 59. Global PD-1 Antibody Drug Revenue Market Share by Type (2026-2031)

Table 60. Global PD-1 Antibody Drug Price (US$/Unit) by Type (2020-2025)

Table 61. Global PD-1 Antibody Drug Price (US$/Unit) by Type (2026-2031)

Table 62. Global PD-1 Antibody Drug Sales (K Units) by Application (2020-2025)

Table 63. Global PD-1 Antibody Drug Sales (K Units) by Application (2026-2031)

Table 64. Global PD-1 Antibody Drug Sales Market Share by Application (2020-2025)

Table 65. Global PD-1 Antibody Drug Sales Market Share by Application (2026-2031)

Table 66. Global PD-1 Antibody Drug Revenue (US$ Million) by Application (2020-2025)

Table 67. Global PD-1 Antibody Drug Revenue (US$ Million) by Application (2026-2031)

Table 68. Global PD-1 Antibody Drug Revenue Market Share by Application (2020-2025)

Table 69. Global PD-1 Antibody Drug Revenue Market Share by Application (2026-2031)

Table 70. Global PD-1 Antibody Drug Price (US$/Unit) by Application (2020-2025)

Table 71. Global PD-1 Antibody Drug Price (US$/Unit) by Application (2026-2031)

Table 72. Merck & Co., Inc. Company Information

Table 73. Merck & Co., Inc. Description and Business Overview

Table 74. Merck & Co., Inc. PD-1 Antibody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 75. Merck & Co., Inc. PD-1 Antibody Drug Product

Table 76. Merck & Co., Inc. Recent Developments/Updates

Table 77. Bristol-Myers Squibb Company Information

Table 78. Bristol-Myers Squibb Description and Business Overview

Table 79. Bristol-Myers Squibb PD-1 Antibody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 80. Bristol-Myers Squibb PD-1 Antibody Drug Product

Table 81. Bristol-Myers Squibb Recent Developments/Updates

Table 82. Regeneron Pharmaceuticals Company Information

Table 83. Regeneron Pharmaceuticals Description and Business Overview

Table 84. Regeneron Pharmaceuticals PD-1 Antibody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 85. Regeneron Pharmaceuticals PD-1 Antibody Drug Product

Table 86. Regeneron Pharmaceuticals Recent Developments/Updates

Table 87. Shanghai Junshi Biosciences Company Information

Table 88. Shanghai Junshi Biosciences Description and Business Overview

Table 89. Shanghai Junshi Biosciences PD-1 Antibody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 90. Shanghai Junshi Biosciences PD-1 Antibody Drug Product

Table 91. Shanghai Junshi Biosciences Recent Developments/Updates

Table 92. Innovent Biologics Company Information

Table 93. Innovent Biologics Description and Business Overview

Table 94. Innovent Biologics PD-1 Antibody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 95. Innovent Biologics PD-1 Antibody Drug Product

Table 96. Innovent Biologics Recent Developments/Updates

Table 97. Hengrui Pharma Company Information

Table 98. Hengrui Pharma Description and Business Overview

Table 99. Hengrui Pharma PD-1 Antibody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 100. Hengrui Pharma PD-1 Antibody Drug Product

Table 101. Hengrui Pharma Recent Developments/Updates

Table 102. BeiGene Company Information

Table 103. BeiGene Description and Business Overview

Table 104. BeiGene PD-1 Antibody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 105. BeiGene PD-1 Antibody Drug Product

Table 106. BeiGene Recent Developments/Updates

Table 107. Akeso, Inc. Company Information

Table 108. Akeso, Inc. Description and Business Overview

Table 109. Akeso, Inc. PD-1 Antibody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 110. Akeso, Inc. PD-1 Antibody Drug Product

Table 111. Akeso, Inc. Recent Developments/Updates

Table 112. Zai Lab Company Information

Table 113. Zai Lab Description and Business Overview

Table 114. Zai Lab PD-1 Antibody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 115. Zai Lab PD-1 Antibody Drug Product

Table 116. Zai Lab Recent Developments/Updates

Table 117. GSK Company Information

Table 118. GSK Description and Business Overview

Table 119. GSK PD-1 Antibody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 120. GSK PD-1 Antibody Drug Product

Table 121. GSK Recent Developments/Updates

Table 122. Eisai Company Information

Table 123. Eisai Description and Business Overview

Table 124. Eisai PD-1 Antibody Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 125. Eisai PD-1 Antibody Drug Product

Table 126. Eisai Recent Developments/Updates

Table 127. Key Raw Materials Lists

Table 128. Raw Materials Key Suppliers Lists

Table 129. PD-1 Antibody Drug Distributors List

Table 130. PD-1 Antibody Drug Customers List

Table 131. PD-1 Antibody Drug Market Trends

Table 132. PD-1 Antibody Drug Market Drivers

Table 133. PD-1 Antibody Drug Market Challenges

Table 134. PD-1 Antibody Drug Market Restraints

Table 135. Research Programs/Design for This Report

Table 136. Key Data Information from Secondary Sources

Table 137. Key Data Information from Primary Sources

Table 138. Authors List of This Report

List of Figures

Figure 1. Product Picture of PD-1 Antibody Drug

Figure 2. Global PD-1 Antibody Drug Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global PD-1 Antibody Drug Market Share by Type: 2024 & 2031

Figure 4. Pembrolizumab Product Picture

Figure 5. Nivolumab Product Picture

Figure 6. Cemiplimab Product Picture

Figure 7. Toripalimab Product Picture

Figure 8. Sintilimab Product Picture

Figure 9. Tislelizumab Product Picture

Figure 10. Camrelizumab Product Picture

Figure 11. Penpulimab Product Picture

Figure 12. Retifanlimab Product Picture

Figure 13. Global PD-1 Antibody Drug Market Value by Dosage Strength, (US$ Million) & (2020-2031)

Figure 14. Global PD-1 Antibody Drug Market Share by Dosage Strength: 2024 VS 2031

Figure 15. 100 mg / Vial Product Picture

Figure 16. 200 mg / Vial Product Picture

Figure 17. 240 mg / Vial Product Picture

Figure 18. Others Product Picture

Figure 19. Global PD-1 Antibody Drug Market Value by Injection Method, (US$ Million) & (2020-2031)

Figure 20. Global PD-1 Antibody Drug Market Share by Injection Method: 2024 VS 2031

Figure 21. Intravenous Injection Product Picture

Figure 22. Subcutaneous Injection Product Picture

Figure 23. Global PD-1 Antibody Drug Market Value by Application (2020-2031) & (US$ Million)

Figure 24. Global PD-1 Antibody Drug Market Share by Application: 2024 & 2031

Figure 25. Hospital

Figure 26. Clinic

Figure 27. Other

Figure 28. Global PD-1 Antibody Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 29. Global PD-1 Antibody Drug Market Size (2020-2031) & (US$ Million)

Figure 30. Global PD-1 Antibody Drug Sales (2020-2031) & (K Units)

Figure 31. Global PD-1 Antibody Drug Average Price (US$/Unit) & (2020-2031)

Figure 32. PD-1 Antibody Drug Report Years Considered

Figure 33. PD-1 Antibody Drug Sales Share by Manufacturers in 2024

Figure 34. Global PD-1 Antibody Drug Revenue Share by Manufacturers in 2024

Figure 35. Global 5 and 10 Largest PD-1 Antibody Drug Players: Market Share by Revenue in PD-1 Antibody Drug in 2024

Figure 36. PD-1 Antibody Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 37. Global PD-1 Antibody Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 38. North America PD-1 Antibody Drug Sales Market Share by Country (2020-2031)

Figure 39. North America PD-1 Antibody Drug Revenue Market Share by Country (2020-2031)

Figure 40. United States PD-1 Antibody Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Canada PD-1 Antibody Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Europe PD-1 Antibody Drug Sales Market Share by Country (2020-2031)

Figure 43. Europe PD-1 Antibody Drug Revenue Market Share by Country (2020-2031)

Figure 44. Germany PD-1 Antibody Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. France PD-1 Antibody Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. U.K. PD-1 Antibody Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Italy PD-1 Antibody Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Russia PD-1 Antibody Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Asia Pacific PD-1 Antibody Drug Sales Market Share by Region (2020-2031)

Figure 50. Asia Pacific PD-1 Antibody Drug Revenue Market Share by Region (2020-2031)

Figure 51. China PD-1 Antibody Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Japan PD-1 Antibody Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. South Korea PD-1 Antibody Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. India PD-1 Antibody Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 55. Australia PD-1 Antibody Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 56. China Taiwan PD-1 Antibody Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 57. Southeast Asia PD-1 Antibody Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 58. Latin America PD-1 Antibody Drug Sales Market Share by Country (2020-2031)

Figure 59. Latin America PD-1 Antibody Drug Revenue Market Share by Country (2020-2031)

Figure 60. Mexico PD-1 Antibody Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 61. Brazil PD-1 Antibody Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 62. Argentina PD-1 Antibody Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 63. Middle East and Africa PD-1 Antibody Drug Sales Market Share by Country (2020-2031)

Figure 64. Middle East and Africa PD-1 Antibody Drug Revenue Market Share by Country (2020-2031)

Figure 65. Turkey PD-1 Antibody Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 66. Saudi Arabia PD-1 Antibody Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 67. UAE PD-1 Antibody Drug Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 68. Global Sales Market Share of PD-1 Antibody Drug by Type (2020-2031)

Figure 69. Global Revenue Market Share of PD-1 Antibody Drug by Type (2020-2031)

Figure 70. Global PD-1 Antibody Drug Price (US$/Unit) by Type (2020-2031)

Figure 71. Global Sales Market Share of PD-1 Antibody Drug by Application (2020-2031)

Figure 72. Global Revenue Market Share of PD-1 Antibody Drug by Application (2020-2031)

Figure 73. Global PD-1 Antibody Drug Price (US$/Unit) by Application (2020-2031)

Figure 74. PD-1 Antibody Drug Value Chain

Figure 75. Channels of Distribution (Direct Vs Distribution)

Figure 76. Bottom-up and Top-down Approaches for This Report

Figure 77. Data Triangulation

Figure 78. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions